KERN PHARMA Repaglinide tablets 17/10/11
KERN PHARMA, presents a new pharmaceutical product, Kern Pharma Repaglinide tablets distributed in tablets and is indicated in patients with type 2 diabetes whose hyperglycemia can not be controlled by diet, weight reduction and exercise.
It is indicated in combination with metformin. The oral hypoglycemic should not be administered in patients with type 1 diabetes with diabetic ketoacidosis and severe disturbances of liver function. This specialty is funded by the National Health System. KERN PHARMA Repaglinide tablets are available in three forms:
KERN PHARMA Repaglinide 0.5 mg 90 tablets
KERN PHARMA Repaglinide 1 mg 90 tablets
KERN PHARMA Repaglinide 2 mg 90 tablets